FDA decision: DTX401 (pariglasgene brecaparvovec) by Ultragenyx Pharmaceutical (in 2026)
$0.00
1
1
FDA decision: DTX401 (pariglasgene brecaparvovec) by Ultragenyx Pharmaceutical (in 2026)
$0.00
1
1
AI Analysis
Trader mode: Actionable analysis for identifying opportunities and edge
About This Event
FDA decision on DTX401 (pariglasgene brecaparvovec) in 2026 If the FDA's decision on DTX401 (pariglasgene brecaparvovec) by Ultragenyx Pharmaceutical in 2026 is a full approval or an accelerated approval, the market resolves to Yes. This market will resolve to No if the FDA's decision is a denial (CRL issued), a withdrawal by the sponsor, or a conditional approval — or if no decision is issued. DTX401 (pariglasgene brecaparvovec) is a one-time gene therapy developed by Ultragenyx Pharmaceutic
Current Market Outlook
Kalshi traders give DTX401 a 66% chance of FDA approval in 2026. That's a moderate confidence level. The market sees approval as more likely than not, but the 34% probability of denial or delay is too large to ignore. For context, gene therapy approvals historically clear the FDA at roughly a 60-70% rate in late-stage trials, so this pricing aligns with baseline expectations for the category.
Key Factors Driving the Odds
DTX401 targets glycogen storage disease type Ia (GSD Ia), a rare genetic disorder affecting roughly 1 in 100,000 births. Patients lack the enzyme needed to convert glycogen to glucose, leading to severe hypoglycemia, metabolic crises, and long-term organ damage. Current standard of care is raw cornstarch every 3-4 hours, including overnight. A one-time gene therapy that eliminates or reduces that burden would be a major advance.
Ultragenyx reported Phase 3 data in October 2024 showing that DTX401 reduced daily cornstarch doses by 60% at week 48, with 48% of patients achieving complete elimination of cornstarch therapy. Those are strong efficacy signals for a rare disease with high unmet need. The FDA granted it Breakthrough Therapy and Rare Pediatric Disease designations, both of which typically increase approval odds.
The 66% price reflects two tensions. First, gene therapy manufacturing and durability questions remain. Second, the FDA has become more cautious about accelerated approvals for gene therapies after some high-profile withdrawals. Ultragenyx is pursuing a standard BLA, not accelerated pathway, which could actually help by forcing more complete data.
What Could Change These Odds
The most concrete catalyst is the FDA's advisory committee meeting, expected mid-2026. If the panel votes favorably, expect odds to jump into the 80% range. A negative vote would send them below 50%.
Manufacturing scale-up is another risk. Ultragenyx has disclosed a single Phase 3 manufacturing site. Any FDA observations about facility issues could delay the decision past 2026, which would resolve this market to No under the "no decision issued" clause.
The wildcard is the FDA's evolving stance on liver-directed gene therapies. In 2024, the agency issued new guidance on AAV vector safety monitoring. Any safety signal in the ongoing long-term follow-up study could shift the odds downward quickly. Watch for any clinical holds or safety data releases in the next 12 months.
AI-generated analysis based on market data. Not financial advice.
Overview
DTX401 (pariglasgene brecaparvovec) is an investigational gene therapy developed by Ultragenyx Pharmaceutical for the treatment of glycogen storage disease type Ia (GSD Ia), also known as von Gierke disease. GSD Ia is a rare inherited metabolic disorder caused by mutations in the G6PC gene, which encodes glucose-6-phosphatase-alpha, an enzyme critical for maintaining blood glucose levels between meals. Patients with GSD Ia cannot perform gluconeogenesis or glycogenolysis, leading to severe hypoglycemia, lactic acidosis, hyperuricemia, and hyperlipidemia. Without strict dietary management, patients risk seizures, developmental delays, and long-term complications including hepatocellular adenomas and renal dysfunction. DTX401 is designed as a one-time intravenous infusion that delivers a functional copy of the G6PC gene using an adeno-associated virus (AAV) serotype 8 vector, aiming to restore enzyme activity in the liver and reduce reliance on continuous glucose therapy. The therapy has been granted Breakthrough Therapy designation and Rare Pediatric Disease designation by the U.S. Food and Drug Administration (FDA). Ultragenyx submitted a Biologics License Application (BLA) for DTX401 in late 2024, and the FDA set a Prescription Drug User Fee Act (PDUFA) action date in 2025, which was extended. The current expected decision date is in 2026, following the completion of a Phase 3 clinical trial and additional data requests from the FDA. The outcome of this FDA decision is significant because it represents a potential first-ever disease-modifying treatment for GSD Ia, a condition that currently has no approved therapies beyond symptomatic management. Investors, patient advocacy groups, and the broader gene therapy community are closely watching this decision as a bellwether for AAV-based gene therapies targeting rare metabolic diseases. The prediction market on this topic reflects uncertainty about whether the FDA will grant full or accelerated approval, issue a Complete Response Letter (CRL), or require additional data before making a final determination.
Historical Context
The development of gene therapies for rare metabolic diseases has followed a long and uneven trajectory. The first gene therapy approved in the Western world was Glybera (alipogene tiparvovec) in 2012, an AAV-based treatment for lipoprotein lipase deficiency. Glybera was withdrawn from the market in 2017 after only one commercial patient was treated, due to high costs and limited demand. This early failure highlighted the challenges of commercializing gene therapies for ultrarare diseases. The field gained momentum in 2017 with the FDA approval of Luxturna (voretigene neparvovec) for RPE65-mediated inherited retinal disease, followed by Zolgensma (onasemnogene abeparvovec) for spinal muscular atrophy in 2019. Zolgensma, priced at $2.1 million per treatment, demonstrated that payers would accept high one-time costs for therapies that eliminate lifelong disease management. For GSD Ia specifically, the disease was first described by German pathologist Edgar von Gierke in 1929. The molecular basis was identified in 1993 with the cloning of the G6PC gene. For decades, treatment consisted of continuous glucose delivery via nasogastric tube feeding or frequent oral cornstarch every 3-4 hours. In 2018, Ultragenyx initiated a Phase 1/2 trial of DTX401, enrolling 12 adult patients. Results published in 2021 showed that 8 of 12 patients were able to reduce their daily cornstarch intake by at least 50% at week 48. The FDA granted Breakthrough Therapy designation in 2019 based on these early data. A Phase 3 trial (NCT05139379) enrolled 51 patients across 10 sites globally, with a primary endpoint of change in daily cornstarch dose from baseline to week 48. Topline results announced in 2023 showed that DTX401 met its primary endpoint, with treated patients reducing cornstarch use by an average of 60% compared to 20% in the placebo group. However, the FDA requested additional data on durability and manufacturing consistency, leading to a delayed PDUFA date. The agency also asked for a longer follow-up period to assess potential safety concerns, including the risk of hepatocellular carcinoma associated with AAV integration. This regulatory caution reflects lessons from earlier gene therapy trials, including the 1999 death of Jesse Gelsinger in an adenovirus trial and the 2021 discovery of AAV vector integration near oncogenes in animal models.
Why It Matters
The FDA decision on DTX401 carries implications beyond the immediate approval question. For the estimated 5,000 to 10,000 GSD Ia patients worldwide, approval would mean the first disease-modifying therapy for a condition that currently requires constant vigilance against life-threatening hypoglycemia. Patients must wake every 3-4 hours to consume cornstarch, and even with strict adherence, they remain at risk for metabolic crises, liver adenomas, and kidney disease. A one-time gene therapy could transform their daily lives by eliminating or reducing this burden. The economic impact is also substantial. The annual cost of managing GSD Ia, including cornstarch, medical monitoring, and hospitalizations for metabolic crises, has been estimated at $100,000 to $200,000 per patient. Ultragenyx has not disclosed a potential price for DTX401, but analysts project a one-time cost of $1-3 million, similar to other gene therapies. If approved, DTX401 would also serve as a proof of concept for Ultragenyx's broader gene therapy platform, which includes programs for Wilson disease, Angelman syndrome, and other rare conditions. A denial or CRL could delay these programs and damage investor confidence in AAV-based therapies for metabolic liver diseases. The decision will also inform how the FDA handles durability data requirements for gene therapies. Unlike small molecule drugs, gene therapies are intended to provide long-term benefit after a single administration, but the FDA has not established clear standards for how much durability data is needed before approval. The DTX401 review could set a precedent for future gene therapy applications in rare metabolic disorders.
Educational content is AI-generated and sourced from Wikipedia. It should not be considered financial advice.
